Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients

DOI: 10.1111/1759-7714.12998
Thoracic Cancer, 2019, 10, 775-781.

#	Paper	IF	Citations
52	Docetaxel/nivolumab/ramucirumab. *Reactions Weekly*, **2019**, 1754, 135-135	0	
51	Clinical utility of ramucirumab in non-small-cell lung cancer. *Biologics: Targets and Therapy*, **2019**, 13, 133-137	4.4	3
50	Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer. *Clinical Case Reports (discontinued)*, **2019**, 7, 1729-1734	0.7	2
49	Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. *Cancer Chemotherapy and Pharmacology*, **2019**, 84, 873-880	3.5	18
48	Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy. *Anticancer Research*, **2019**, 39, 4987-4993	2.3	15
47	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. *Translational Lung Cancer Research*, **2019**, 8, 450-460	4.4	8
46	Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer. *Thoracic Cancer*, **2019**, 10, 1005-1008	3.2	4
45	Pseudo-Progression and the Neutrophil-to-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Case-Control Study. *OncoTargets and Therapy*, **2019**, 12, 10559-10568	4.4	11
44	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. *Clinical and Translational Oncology*, **2020**, 22, 759-771	3.6	10
43	Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. *Lung Cancer*, **2020**, 140, 8-18	5.9	37
42	Treatment after progression in the era of immunotherapy. *Lancet Oncology, The*, **2020**, 21, e463-e476	21.7	50
41	[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management]. *Bulletin Du Cancer*, **2020**, 107, 779-791	2.4	0
40	Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920937902	5.4	13
39	Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). *BMC Cancer*, **2020**, 20, 1185	4.8	24
38	A case of multiple metastatic gastric cancer with primary lesion vanished after administrating nivolumab, and the effect remains even after discontinuance of therapy. *International Cancer Conference Journal*, **2020**, 9, 187-192	0.9	1
37	Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. *ESMO Open*, **2020**, 4,	6	2
36	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. *JAMA Oncology*, **2020**, 6, 1571-1580	13.4	196

35	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. *Clinical Medicine Insights: Oncology*, **2020**, 14, 1179554920951358	1.8	8
34	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. *Respiration*, **2020**, 1-27	3.7	6
33	Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?. *Lung Cancer*, **2020**, 144, 76-84	5.9	14
32	Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment. *Lung Cancer*, **2020**, 144, 71-75	5.9	6
31	Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, **2020**, 12, e1612	9.2	10
30	Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC. *Anticancer Research*, **2020**, 40, 1571-1578	2.3	
29	Current status of immunotherapy for advanced gastric cancer. *Japanese Journal of Clinical Oncology* , **2021**, 51, 20-27	2.8	10
28	Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer. *Thoracic Cancer*, **2021**, 12, 1171-1179	3.2	1
27	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. *Blood Advances*, **2021**, 5, 1648-1659	7.8	6
26	Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study. *Translational Lung Cancer Research*, **2021**, 10, 1642-1652	4.4	2
25	The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study. *Frontiers in Oncology*, **2021**, 11, 663612	5.3	4
24	Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. *Future Oncology*, **2021**, 17, 3965-3976	3.6	1
23	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. *Translational Lung Cancer Research*, **2021**, 10, 3093-3105	4.4	2
22	The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer. *Journal of Cancer Research and Clinical Oncology*, **2021**, 1	4.9	1
21	Immune Therapy: What Can We Learn From Acquired Resistance?. *Current Cancer Research*, **2021**, 75-114	0.2	
20	Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment. *Respirology Case Reports*, **2020**, 8, e00564	0.9	3
19	Decoding cancer‘s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade.. **2020**, 3, 832-853		4
18	New Strategies in the Treatment of Advanced Squamous Non-Small Cell Lung Cancer. *Japanese Journal of Lung Cancer*, **2020**, 60, 379-384	0.1	

17	Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. *Critical Reviews in Oncology/Hematology*, **2021**, 169, 103538	7	2
16	Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study. *Thoracic Cancer*, **2021**, 13, 173	3.2	1
15	Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study.. *Clinical Oncology*, **2022**,	2.8	1
14	Immunotherapy for Gastroesophageal Tumors: Is There Still Hope for Efficacy?. *Current Cancer Drug Targets*, **2022**,	2.8	
13	Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor Failure in Patients with Advanced Non-Small-Cell Lung Cancer: A Case Series.. *Case Reports in Oncology*, **2022**, 15, 138-148	1	1
12	Re-evaluating Subsequent Treatment Options in Non-small Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.. *Clinical Oncology*, **2022**,	2.8	
11	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. *Journal of Clinical Oncology*,	2.2	4
10	Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. *Journal of Clinical Oncology*,	2.2	0
9	Paclitaxel-Bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study. *Therapeutic Advances in Medical Oncology*, **2022**, 14, 175883592210993	5.4	0
8	Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?. *Cancers*, **2022**, 14, 2970	6.6	1
7	Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer. *Investigational New Drugs*,	4.3	1
6	Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy. **2022**, 14, 3953		
5	Immunotherapy in advanced NSCLC without driver mutations: available therapeutic alternatives after progression and future treatment options. **2022**,		1
4	Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). **2023**, 184, 62-72		0
3	Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. **2023**, 179, 107173		0
2	Eosinophil and IFN- associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy. 14,		0
1	Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.		0